Physician profile
Christy Graves
NPI 1013051036
$8,587.69
in general payments reported to CMS, 2019-2025
37 companies · $713 in 2025
The $713 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,568 · 2020: $1,462 · 2021: $1,763 · 2022: $1,377 · 2023: $1,076 · 2024: $628 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,417.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,094.42 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,020.53 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $937.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $773.37 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $732.60 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $423.75 | 2019-2023 | Belsomra, Verquvo, Steglatro |
| Allergan, INC. | $414.90 | 2019-2020 | |
| Lilly USA, LLC | $359.33 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Ironwood Pharmaceuticals, INC | $348.22 | 2019-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $254.88 | 2019-2024 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $242.60 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.83 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $200.93 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $182.80 | 2019-2024 | Rexulti |
| Astellas Pharma US INC | $175.11 | 2019-2025 | Veozah, Myrbetriq |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christy Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.